Natera, Inc. (NASDAQ:NTRA) CEO Sells $225,928.38 in Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 1,622 shares of the stock in a transaction on Monday, July 21st. The stock was sold at an average price of $139.29, for a total value of $225,928.38. Following the transaction, the chief executive officer owned 175,492 shares of the company's stock, valued at $24,444,280.68. This represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, July 1st, Steven Leonard Chapman sold 5,343 shares of Natera stock. The shares were sold at an average price of $166.53, for a total value of $889,769.79.
• On Monday, June 2nd, Steven Leonard Chapman sold 6,111 shares of Natera stock. The shares were sold at an average price of $157.10, for a total value of $960,038.10.
• On Thursday, May 1st, Steven Leonard Chapman sold 6,980 shares of Natera stock. The stock was sold at an average price of $150.10, for a total transaction of $1,047,698.00.
• On Monday, April 28th, Steven Leonard Chapman sold 6,203 shares of Natera stock. The shares were sold at an average price of $152.18, for a total value of $943,972.54.

Natera Stock Up 2.4%

NASDAQ NTRA traded up $3.25 on Thursday, hitting $141.07. The company's stock had a trading volume of 1,421,449 shares, compared to its average volume of 1,212,550. The firm has a market cap of $19.26 billion, a PE ratio of -95.97 and a beta of 1.73. The company's 50-day moving average is $159.24 and its 200 day moving average is $157.55. Natera, Inc. has a 1-year low of $92.14 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The company had revenue of $501.83 million during the quarter, compared to analysts' expectations of $446.68 million. During the same period in the prior year, the company posted ($0.56) earnings per share. Natera's revenue for the quarter was up 36.5% compared to the same quarter last year. On average, equities analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Hedge Funds Weigh In On Natera

Institutional investors have recently modified their holdings of the company. Callan Family Office LLC acquired a new stake in Natera in the 2nd quarter valued at $610,000. Vontobel Holding Ltd. lifted its stake in shares of Natera by 58.3% in the second quarter. Vontobel Holding Ltd. now owns 2,917 shares of the medical research company's stock valued at $493,000 after buying an additional 1,074 shares in the last quarter. Maryland State Retirement & Pension System lifted its stake in shares of Natera by 17.9% in the second quarter. Maryland State Retirement & Pension System now owns 6,311 shares of the medical research company's stock valued at $1,066,000 after buying an additional 959 shares in the last quarter. Narwhal Capital Management grew its holdings in shares of Natera by 33.3% during the second quarter. Narwhal Capital Management now owns 13,325 shares of the medical research company's stock valued at $2,251,000 after buying an additional 3,332 shares during the last quarter. Finally, KLP Kapitalforvaltning AS increased its position in shares of Natera by 1.8% during the second quarter. KLP Kapitalforvaltning AS now owns 44,400 shares of the medical research company's stock worth $7,501,000 after acquiring an additional 800 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently weighed in on NTRA shares. Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. UBS Group raised their price target on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. Piper Sandler lifted their price objective on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Thursday, May 15th. Finally, Barclays upped their price objective on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $184.63.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.